These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 36398557)

  • 21. Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease.
    Ferla R; Claudiani P; Cotugno G; Saccone P; De Leonibus E; Auricchio A
    Hum Gene Ther; 2014 Jul; 25(7):609-18. PubMed ID: 24725025
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Marcó S; Haurigot V; Bosch F
    Hum Gene Ther; 2019 Oct; 30(10):1211-1221. PubMed ID: 31482754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene therapy for lysosomal storage disorders.
    Ioannou YA; Enriquez A; Benjamin C
    Expert Opin Biol Ther; 2003 Aug; 3(5):789-801. PubMed ID: 12880379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy for lysosomal storage diseases and peroxisomal diseases.
    Ohashi T
    J Hum Genet; 2019 Feb; 64(2):139-143. PubMed ID: 30498239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Approaches in Lysosomal Storage Diseases.
    Fernández-Pereira C; San Millán-Tejado B; Gallardo-Gómez M; Pérez-Márquez T; Alves-Villar M; Melcón-Crespo C; Fernández-Martín J; Ortolano S
    Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy for lysosomal storage disorders.
    Gritti A
    Expert Opin Biol Ther; 2011 Sep; 11(9):1153-67. PubMed ID: 21548845
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Poletto E; Silva AO; Weinlich R; Martin PKM; Torres DC; Giugliani R; Baldo G
    Expert Opin Biol Ther; 2023 Apr; 23(4):353-364. PubMed ID: 36920351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy.
    Hurlbut GD; Ziegler RJ; Nietupski JB; Foley JW; Woodworth LA; Meyers E; Bercury SD; Pande NN; Souza DW; Bree MP; Lukason MJ; Marshall J; Cheng SH; Scheule RK
    Mol Ther; 2010 Nov; 18(11):1983-94. PubMed ID: 20736932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysosomal storage disorders: old diseases, present and future challenges.
    Klein AD; Futerman AH
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():59-63. PubMed ID: 24380123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment options for lysosomal storage disorders: developing insights.
    van Gelder CM; Vollebregt AA; Plug I; van der Ploeg AT; Reuser AJ
    Expert Opin Pharmacother; 2012 Nov; 13(16):2281-99. PubMed ID: 23009070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.
    Penati R; Fumagalli F; Calbi V; Bernardo ME; Aiuti A
    J Inherit Metab Dis; 2017 Jul; 40(4):543-554. PubMed ID: 28560469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID.
    Roca C; Motas S; Marcó S; Ribera A; Sánchez V; Sánchez X; Bertolin J; León X; Pérez J; Garcia M; Villacampa P; Ruberte J; Pujol A; Haurigot V; Bosch F
    Hum Mol Genet; 2017 Apr; 26(8):1535-1551. PubMed ID: 28334745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel treatment for neuronopathic lysosomal storage diseases--cell therapy/gene therapy.
    Eto Y; Ohashi T
    Curr Mol Med; 2002 Feb; 2(1):83-9. PubMed ID: 11898850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases.
    Gurda BL; Vite CH
    Hum Mol Genet; 2019 Oct; 28(R1):R119-R131. PubMed ID: 31384936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapies for neuropathic lysosomal storage disorders.
    Kelly JM; Bradbury A; Martin DR; Byrne ME
    Prog Neurobiol; 2017 May; 152():166-180. PubMed ID: 27725193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene transfer strategies for correction of lysosomal storage disorders.
    D'Azzo A
    Acta Haematol; 2003; 110(2-3):71-85. PubMed ID: 14583667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.